Epizyme, Inc. (EPZM) Stake Held by UBS Asset Management Americas Inc.
UBS Asset Management Americas Inc. continued to hold its position in shares of Epizyme, Inc. (NASDAQ:EPZM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,200 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. UBS Asset Management Americas Inc.’s holdings in Epizyme were worth $154,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Legal & General Group Plc grew its stake in Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 795 shares during the last quarter. BB&T Securities LLC purchased a new stake in Epizyme during the 2nd quarter valued at about $181,000. Trexquant Investment LP purchased a new stake in Epizyme during the 2nd quarter valued at about $184,000. SG Americas Securities LLC grew its stake in Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 6,072 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new stake in shares of Epizyme in the second quarter worth about $215,000. Institutional investors and hedge funds own 72.20% of the company’s stock.
Epizyme, Inc. (NASDAQ EPZM) opened at $13.90 on Wednesday. Epizyme, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $20.45.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. research analysts anticipate that Epizyme, Inc. will post -2.22 EPS for the current fiscal year.
A number of analysts have recently commented on the company. Jefferies Group LLC assumed coverage on Epizyme in a research note on Wednesday, September 20th. They issued a “buy” rating and a $23.00 target price on the stock. Cann restated a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Monday, October 16th. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $20.00 target price on shares of Epizyme in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. Epizyme presently has an average rating of “Buy” and a consensus price target of $22.67.
COPYRIGHT VIOLATION WARNING: “Epizyme, Inc. (EPZM) Stake Held by UBS Asset Management Americas Inc.” was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/08/epizyme-inc-epzm-stake-held-by-ubs-asset-management-americas-inc.html.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total value of $246,600.00. Following the completion of the transaction, the insider now owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David M. Mott purchased 200,000 shares of Epizyme stock in a transaction that occurred on Monday, September 18th. The stock was acquired at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at approximately $91,500. The disclosure for this purchase can be found here. Insiders sold a total of 45,000 shares of company stock valued at $733,950 in the last ninety days. 25.20% of the stock is currently owned by insiders.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.